The field of adoptive cell therapy has witnessed a game-changing development: metabolic reprogramming is now revolutionizing how we boost CD8+ T cell performance. While conventional methods tweak receptor signals or add cytokines, we're finding that rewiring the cells' own metabolic machinery creates tougher, longer-lasting fighters - especially against tumors' immunosuppressive tactics. Gene editing technologies, particularly those enabling targeted and stable modifications, have become indispensable tools in fine-tuning these metabolic pathways. At Creative Biolabs, we offer comprehensive gene editing services to support metabolic optimization of CD8+ T cells for both research and therapeutic development.
Fig.1 Schematic diagram of knockout screening of primary CD8 T cells.1
Our service portfolio is built to support a broad spectrum of CD8+ T cell metabolism studies. Whether the goal is to enhance glycolysis, mitochondrial fitness, or fatty acid metabolism, our gene editing solutions help clients achieve desired cellular traits. Services include:
All gene editing is performed in primary human or murine CD8+ T cells with rigorous functional validation post-modification.
To accommodate diverse project requirements in CD8+ T cell metabolic reprogramming, Creative Biolabs employs a suite of precision editing platforms built upon engineered nucleases and transcriptional regulators. These platforms allow for efficient and targeted genomic manipulation with minimal off-target effects.
We utilize highly adaptable editing tools capable of inducing gene disruption or precise sequence insertion at targeted genomic loci. These systems are optimized for robust performance in primary T cells and enable the modulation of genes involved in glycolysis, mitochondrial dynamics, fatty acid metabolism, and more.
Our gene regulation platforms allow for reversible upregulation or suppression of metabolic genes through targeted binding to promoter regions. This non-destructive approach is ideal for studying gene function in a tunable and temporal manner.
For sensitive applications where maintaining genome integrity is critical, we offer editing strategies that do not rely on direct DNA cleavage. These approaches support the modification of gene expression levels while avoiding permanent genomic changes.
Depending on the nature of the target and cell type, we employ viral vectors or physical delivery methods (e.g., electroporation) to maximize efficiency, cell viability, and functional output in edited CD8+ T cells.
To streamline your research process, we've designed a transparent and customizable workflow:
We are more than a gene editing service provider—we are your strategic partner in T cell metabolic research. What sets us apart:
Metabolism-Focused Expertise: Deep understanding of T cell bioenergetics and immunometabolism.
High Editing Efficiency: Proprietary electroporation and culture methods to maximize viability and edit rate.
Strict QC Standards: Rigorous quality control at each step to ensure reproducibility and functional relevance.
Flexible & Customizable: Services can be adapted to fit different disease models, experimental endpoints, and cell sources.
Our gene editing toolkit can reprogram T cell metabolism to boost your therapy's performance.
Let's make it happen:
We'll schedule a 30-min consult to understand your exact needs;
Get a tailored solution designed for your specific research goals;
No canned proposals - just smart science made for your project.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION